West Haven, Connecticut 06516

  • Schizoaffective Disorder


This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained benefit from cognitive retraining.

Study summary:

Patients with schizophrenia or schizoaffective disorder who are currently receiving antipsychotic medication will be randomly assigned in a double-blind manner to receive either D-serine (30 mg/kg) or placebo in addition to cognitive rehabilitation or a non-interactive placebo for 12 weeks.


Inclusion Criteria: - Diagnosis of schizophrenia or schizoaffective disorder Exclusion - Pregnant or lactating



Primary Contact:

Principal Investigator
Deepak C D'Souza, M.D.
Yale University

Rajiv Radhakrishnan, MD
Phone: 203-932-5711 ext. 3921
Email: rajiv.radhakrishnan@yale.edu

Backup Contact:


Location Contact:

West Haven, Connecticut 06516
United States

Rajiv Radhakrishnan, MD
Phone: 203-932-5711
Email: rajiv.radhakrishnan@yale.edu

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: September 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.